The thesis on the analysis of the clinical trial of the Covid-19 vaccine phase III made by Sinopharm was officially published in the Journal of the American Medical Association (JAMA) last Wednesday (26/5). Research shows, the protective effect of the two kinds of vaccines reached 72.8 percent and 78.1 percent, respectively. This is the result of the first phase III clinical trial of the Covid-19 vaccine, which was officially published worldwide.
The thesis said, this is only the result of the analysis while the phase III clinical trial, researchers are still collecting more data, and continue to evaluate the issue of the vaccine’s long-term protective effect, prevention of serious illness and death and immune resistance to obtain final analysis results
–
